Literature DB >> 9723964

Control of arterial tone after long-term coenzyme Q10 supplementation in senescent rats.

K Lönnrot1, I Pörsti, H Alho, X Wu, A Hervonen, J P Tolvanen.   

Abstract

1. Age-associated deterioration of arterial function may result from long-lasting oxidative stress. Since coenzyme Q (Q10) has been suggested to protect the vascular endothelium from free radical-induced damage, we investigated the effects of long-term dietary Q10 supplementation on arterial function in senescent Wistar rats. 2. At 16 months of age, 18 rats were divided into two groups. The control group was kept on a standard diet while the other group was supplemented with Q10 (10 mg kg(-1) day(-1)). In addition, nine rats (age 2 months) also ingesting a standard diet were used as the young control group. After 8 study weeks the responses of the mesenteric arterial rings in vitro were examined. 3. Endothelium-independent arterial relaxations to isoprenaline and nitroprusside (SNP) were attenuated in aged rats. Increased dietary Q10 clearly enhanced the relaxation to isoprenaline, but did not affect the response to SNP. In addition, vasodilation of noradrenaline-precontracted rings to acetylcholine (ACh), which was also impaired in aged vessels, was improved after Q10 supplementation. Cyclooxygenase inhibition with diclofenac enhanced the relaxation to ACh only in young rats, while it abolished the difference between the old controls and Q10 supplemented rats, suggesting that the improved endothelium-dependent vasodilation observed in Q10 supplemented rats was largely mediated by prostacyclin (PGI2). 4. In conclusion, long-term Q10 supplementation improved endothelium-dependent vasodilation and enhanced beta-adrenoceptor-mediated arterial relaxation in senescent Wistar rats. The mechanisms underlying the improvement of endothelial function may have included augmented endothelial production of PGI2, increased sensitivity of smooth muscle to PGI2, or both.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9723964      PMCID: PMC1565529          DOI: 10.1038/sj.bjp.0701970

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  6 in total

1.  Coenzyme q10 therapy.

Authors:  Juan Garrido-Maraver; Mario D Cordero; Manuel Oropesa-Ávila; Alejandro Fernández Vega; Mario de la Mata; Ana Delgado Pavón; Manuel de Miguel; Carmen Pérez Calero; Marina Villanueva Paz; David Cotán; José A Sánchez-Alcázar
Journal:  Mol Syndromol       Date:  2014-07

2.  Nondrug interventions for the treatment of hypertension: varying effect.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-12-09       Impact factor: 3.738

3.  Effects of coenzyme Q10 on cardiovascular and metabolic biomarkers in overweight and obese patients with type 2 diabetes mellitus: a pooled analysis.

Authors:  Haohai Huang; Honggang Chi; Dan Liao; Ying Zou
Journal:  Diabetes Metab Syndr Obes       Date:  2018-11-29       Impact factor: 3.168

4.  Levels of Plasma Coenzyme Q10 Are Associated with Physical Capacity and Cardiovascular Risk in the Elderly.

Authors:  Rocío de la Bella-Garzón; Cristina Fernández-Portero; David Alarcón; Josué G Amián; Guillermo López-Lluch
Journal:  Antioxidants (Basel)       Date:  2022-01-29

Review 5.  The Use of Coenzyme Q10 in Cardiovascular Diseases.

Authors:  Yoana Rabanal-Ruiz; Emilio Llanos-González; Francisco Javier Alcain
Journal:  Antioxidants (Basel)       Date:  2021-05-10

Review 6.  Mitochondrial dysfunction in obesity: potential benefit and mechanism of Co-enzyme Q10 supplementation in metabolic syndrome.

Authors:  Md Ashraful Alam; Md Mahbubur Rahman
Journal:  J Diabetes Metab Disord       Date:  2014-05-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.